Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute Heart Failure
Robert J. Mentz, Susanna R. Stevens, Adam D. DeVore, Anuradha Lala, Justin M. Vader, Omar F. AbouEzzeddine, Prateeti Khazanie, Margaret M. Redfield, Lynne W. Stevenson, Christopher M. O’Connor, Steven R. Goldsmith, Bradley A. Bart, Kevin J. Anstrom, Adrian F. Hernandez, Eugene Braunwald and G. Michael Felker
PRA Change From Baseline Based on Decongestion Strategy
Values are medians (solid circles) and interquartile ranges (whiskers). p Values were derived from linear regression models for 72- or 96-h plasma renin activity (PRA), adjusted for baseline PRA, use of baseline ACE-I/ARB, and use of baseline aldosterone antagonist where a log transformation was applied to both the baseline and the follow-up PRA measure. ACE-I/ARB = angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; Bolus = bolus furosemide; Contin = continuous infusion furosemide; Low = low-dose furosemide; High = high-dose furosemide; Pharm = stepped pharmacologic therapy; UF = ultrafiltration.